{"title":"作为中枢神经系统药物的新型杂环化合物的计算研究与合成。","authors":"Pooja Saini, Sushil Kumar","doi":"10.2174/1570163820666230918100218","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This research work aimed to design and synthesize some new molecules of phenothiazine. The work's emphasis was on forming new phenothiazines in two series, 1-(10H-phenothiazin- 10-yl)-2-((4-(1-(phenylimino)ethyl)phenyl)amino)ethan-1-one derivatives (4a-4j) and 1-(4-((2-oxo-2- (10H-phenothiazin-10-yl)ethyl)amino)phenyl)-3-phenylprop-2-en-1-one derivatives (P1-P5).</p><p><strong>Methods: </strong>Chloroacetylation of phenothiazine was done to afford 2-chloro-1-(10H-phenothiazin-10- yl)ethan-1-one, which was further reacted with 4-amino acetophenone to produce 2-((4- acetylphenyl)amino)-1-(10H-phenothiazin-10-yl)ethan-1-one. Then, it was treated with substituted anilines and substituted benzaldehydes to produce the final derivatives 4a-4j and P1-P5, respectively.</p><p><strong>Results: </strong>All 15 derivatives (4a-4j and P1-P5) were characterized by evaluating their Rf value, melting point, solubility, IR spectroscopy, and <sup>1</sup>HNMR spectroscopy. Molecular docking was performed by using AutoDock Vina v.1.2.0 (The Scripps Research Institute, La Jolla, CA, USA) docking software, and the anxiolytic activity of the derivatives was assessed by using the elevated plus maze model.</p><p><strong>Conclusion: </strong>The designed scheme was executed in the departmental laboratory. The chemical structure of the compounds was confirmed on the basis of TLC, IR, and <sup>1</sup>HNMR analyses. The docking study revealed a good docking score of the compounds. The Log P value of the compounds indicated their good penetration into CNS. The compounds were also screened for anxiolytic activity. Among them, compounds 4f, 4h, and P3 showed maximum activity as anti-anxiolytic agents.</p>","PeriodicalId":10858,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":"90-99"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Computational Studies and Synthesis of New Heterocyclics as CNS Agents.\",\"authors\":\"Pooja Saini, Sushil Kumar\",\"doi\":\"10.2174/1570163820666230918100218\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>This research work aimed to design and synthesize some new molecules of phenothiazine. The work's emphasis was on forming new phenothiazines in two series, 1-(10H-phenothiazin- 10-yl)-2-((4-(1-(phenylimino)ethyl)phenyl)amino)ethan-1-one derivatives (4a-4j) and 1-(4-((2-oxo-2- (10H-phenothiazin-10-yl)ethyl)amino)phenyl)-3-phenylprop-2-en-1-one derivatives (P1-P5).</p><p><strong>Methods: </strong>Chloroacetylation of phenothiazine was done to afford 2-chloro-1-(10H-phenothiazin-10- yl)ethan-1-one, which was further reacted with 4-amino acetophenone to produce 2-((4- acetylphenyl)amino)-1-(10H-phenothiazin-10-yl)ethan-1-one. Then, it was treated with substituted anilines and substituted benzaldehydes to produce the final derivatives 4a-4j and P1-P5, respectively.</p><p><strong>Results: </strong>All 15 derivatives (4a-4j and P1-P5) were characterized by evaluating their Rf value, melting point, solubility, IR spectroscopy, and <sup>1</sup>HNMR spectroscopy. Molecular docking was performed by using AutoDock Vina v.1.2.0 (The Scripps Research Institute, La Jolla, CA, USA) docking software, and the anxiolytic activity of the derivatives was assessed by using the elevated plus maze model.</p><p><strong>Conclusion: </strong>The designed scheme was executed in the departmental laboratory. The chemical structure of the compounds was confirmed on the basis of TLC, IR, and <sup>1</sup>HNMR analyses. The docking study revealed a good docking score of the compounds. The Log P value of the compounds indicated their good penetration into CNS. The compounds were also screened for anxiolytic activity. Among them, compounds 4f, 4h, and P3 showed maximum activity as anti-anxiolytic agents.</p>\",\"PeriodicalId\":10858,\"journal\":{\"name\":\"Current drug discovery technologies\",\"volume\":\" \",\"pages\":\"90-99\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current drug discovery technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1570163820666230918100218\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug discovery technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1570163820666230918100218","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
摘要
目的:这项研究工作旨在设计和合成一些新的吩噻嗪分子。工作重点是合成两个系列的新吩噻嗪,即 1-(10H-吩噻嗪-10-基)-2-((4-(1-(苯基亚氨基)乙基)苯基)氨基)乙-1-酮衍生物(4a-4j)和 1-(4-((2-氧代-2-(10H-吩噻嗪-10-基)乙基)氨基)苯基)-3-苯基丙-2-烯-1-酮衍生物(P1-P5):将吩噻嗪进行氯乙酰化,得到 2-氯-1-(10H-吩噻嗪-10-基)乙-1-酮,再与 4-氨基苯乙酮反应,得到 2-((4-乙酰苯基)氨基)-1-(10H-吩噻嗪-10-基)乙-1-酮。然后,用取代的苯胺和取代的苯甲醛处理,分别生成最终的衍生物 4a-4j 和 P1-P5:通过评估其 Rf 值、熔点、溶解度、红外光谱和 1HNMR 光谱,对所有 15 种衍生物(4a-4j 和 P1-P5)进行了表征。使用 AutoDock Vina v.1.2.0 (The Scripps Research Institute, La Jolla, CA, USA)对接软件进行了分子对接,并使用高架加迷宫模型评估了衍生物的抗焦虑活性:结论:所设计的方案已在该系实验室实施。结论:所设计的方案在该系实验室得到了实施,化合物的化学结构在 TLC、IR 和 1HNMR 分析的基础上得到了确认。对接研究显示,化合物的对接得分良好。化合物的 Log P 值表明其在中枢神经系统中具有良好的渗透性。还对这些化合物进行了抗焦虑活性筛选。其中,化合物 4f、4h 和 P3 显示出最大的抗焦虑活性。
Computational Studies and Synthesis of New Heterocyclics as CNS Agents.
Aim: This research work aimed to design and synthesize some new molecules of phenothiazine. The work's emphasis was on forming new phenothiazines in two series, 1-(10H-phenothiazin- 10-yl)-2-((4-(1-(phenylimino)ethyl)phenyl)amino)ethan-1-one derivatives (4a-4j) and 1-(4-((2-oxo-2- (10H-phenothiazin-10-yl)ethyl)amino)phenyl)-3-phenylprop-2-en-1-one derivatives (P1-P5).
Methods: Chloroacetylation of phenothiazine was done to afford 2-chloro-1-(10H-phenothiazin-10- yl)ethan-1-one, which was further reacted with 4-amino acetophenone to produce 2-((4- acetylphenyl)amino)-1-(10H-phenothiazin-10-yl)ethan-1-one. Then, it was treated with substituted anilines and substituted benzaldehydes to produce the final derivatives 4a-4j and P1-P5, respectively.
Results: All 15 derivatives (4a-4j and P1-P5) were characterized by evaluating their Rf value, melting point, solubility, IR spectroscopy, and 1HNMR spectroscopy. Molecular docking was performed by using AutoDock Vina v.1.2.0 (The Scripps Research Institute, La Jolla, CA, USA) docking software, and the anxiolytic activity of the derivatives was assessed by using the elevated plus maze model.
Conclusion: The designed scheme was executed in the departmental laboratory. The chemical structure of the compounds was confirmed on the basis of TLC, IR, and 1HNMR analyses. The docking study revealed a good docking score of the compounds. The Log P value of the compounds indicated their good penetration into CNS. The compounds were also screened for anxiolytic activity. Among them, compounds 4f, 4h, and P3 showed maximum activity as anti-anxiolytic agents.
期刊介绍:
Due to the plethora of new approaches being used in modern drug discovery by the pharmaceutical industry, Current Drug Discovery Technologies has been established to provide comprehensive overviews of all the major modern techniques and technologies used in drug design and discovery. The journal is the forum for publishing both original research papers and reviews describing novel approaches and cutting edge technologies used in all stages of drug discovery. The journal addresses the multidimensional challenges of drug discovery science including integration issues of the drug discovery process.